Overview
- Researchers from the University of Houston, Baylor College of Medicine, and MD Anderson report in Gastro Hep Advances that tests in patient‑derived organoids point to a new route to treatment.
- The team links Crohn’s to a chronic integrated stress response in the intestinal lining that keeps a cellular alarm stuck on and triggers necroptosis, an inflammatory form of cell death.
- In these models, low doses of pazopanib and ponatinib curbed the stress signal, reduced necroptosis, and restored barrier repair.
- The findings are preclinical, so the next steps are dose selection, safety evaluations, and early clinical trials in people with Crohn’s disease.
- Only about 20% of patients achieve lasting remission on current anti‑inflammatory drugs, and repurposing approved medicines could speed testing and, if validated, offer a barrier‑healing approach.